关注
Chong-Jen Yu
Chong-Jen Yu
National Taiwan University Hospital
在 ntu.edu.tw 的电子邮件经过验证
标题
引用次数
引用次数
年份
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
J Bean, C Brennan, JY Shih, G Riely, A Viale, L Wang, D Chitale, N Motoi, ...
Proceedings of the National Academy of Sciences 104 (52), 20932-20937, 2007
18722007
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
JC Soria, DSW Tan, R Chiari, YL Wu, L Paz-Ares, J Wolf, SL Geater, ...
The Lancet 389 (10072), 917-929, 2017
10482017
Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
YL Wu, M Tsuboi, J He, T John, C Grohe, M Majem, JW Goldman, ...
New England Journal of Medicine 383 (18), 1711-1723, 2020
9712020
MicroRNA signature predicts survival and relapse in lung cancer
SL Yu, HY Chen, GC Chang, CY Chen, HW Chen, S Singh, CL Cheng, ...
Cancer cell 13 (1), 48-57, 2008
9572008
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3 …
JCH Yang, LV Sequist, SL Geater, CM Tsai, TSK Mok, M Schuler, ...
The lancet oncology 16 (7), 830-838, 2015
8342015
Value of sonography in determining the nature of pleural effusion: analysis of 320 cases.
PC Yang, KT Luh, DB Chang, HD Wu, CJ Yu, SH Kuo
AJR. American journal of roentgenology 159 (1), 29-33, 1992
6381992
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib …
T Mok, YL Wu, JS Lee, CJ Yu, V Sriuranpong, J Sandoval-Tan, G Ladrera, ...
Clinical Cancer Research 21 (14), 3196-3203, 2015
4862015
Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung CancerUncommon EGFR …
JY Wu, CJ Yu, YC Chang, CH Yang, JY Shih, PC Yang
Clinical cancer research 17 (11), 3812-3821, 2011
4552011
Mycobacterium abscessus complex infections in humans
MR Lee, WH Sheng, CC Hung, CJ Yu, LN Lee, PR Hsueh
Emerging infectious diseases 21 (9), 1638, 2015
4432015
Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis
JY Chien, JS Jerng, CJ Yu, PC Yang
Critical care medicine 33 (8), 1688-1693, 2005
3882005
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
YL Wu, JS Lee, S Thongprasert, CJ Yu, L Zhang, G Ladrera, ...
The lancet oncology 14 (8), 777-786, 2013
3852013
Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells
YC Liu, HY Yen, CY Chen, CH Chen, PF Cheng, YH Juan, CH Chen, ...
Proceedings of the National Academy of Sciences 108 (28), 11332-11337, 2011
3622011
Pulmonary Sequelae in Convalescent Patients after Severe Acute Respiratory Syndrome: Evaluation with Thin-Section CT1
YC Chang, CJ Yu, SC Chang, JR Galvin, HM Liu, CH Hsiao, PH Kuo, ...
Radiology 236 (3), 1067-1075, 2005
3472005
Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response
JY Wu, SG Wu, CH Yang, CH Gow, YL Chang, CJ Yu, JY Shih, PC Yang
Clinical Cancer Research 14 (15), 4877-4882, 2008
3342008
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia
Q Lan, CA Hsiung, K Matsuo, YC Hong, A Seow, Z Wang, HD Hosgood III, ...
Nature genetics 44 (12), 1330-1335, 2012
3022012
Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line …
CH Yang, CJ Yu, JY Shih, YC Chang, FC Hu, MC Tsai, KY Chen, ZZ Lin, ...
Journal of Clinical Oncology 26 (16), 2745-2753, 2008
2952008
Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma
JY Shih, MF Tsai, TH Chang, YL Chang, A Yuan, CJ Yu, SB Lin, GY Liou, ...
Clinical Cancer Research 11 (22), 8070-8078, 2005
2842005
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer.
TS Mok, YL Wu, CJ Yu, C Zhou, YM Chen, L Zhang, J Ignacio, M Liao, ...
Oncology, 2008
2772008
Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome
JY CHIEN, PR HSUEH, WC CHENG, CJ YU, PC YANG
Respirology 11 (6), 715-722, 2006
2712006
Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non–small-cell …
A Yuan, CJ Yu, SH Kuo, WJ Chen, FY Lin, KT Luh, PC Yang, YC Lee
Journal of clinical oncology 19 (2), 432-441, 2001
2662001
系统目前无法执行此操作,请稍后再试。
文章 1–20